# Alnylam Pharmaceuticals

> Developing RNAi therapeutics

Business model and tags: B2B, Has physical offices, Publicly traded, Manufacturing, Healthtech, Sales-led purchase, Pharma & life sciences, Multi-site, International operations, Has production sites, Has in-house R&D, Has field sales reps, Handles regulated data

## About Alnylam Pharmaceuticals

A global biotech company pioneering RNAi therapeutics to treat rare genetic diseases, with a breakthrough product and a robust pipeline

## Key facts

- **Industry**: Biotechnology Research
- **Company size**: 1,001–5,000 employees
- **Headquarters**: cambridge, massachusetts, United States
- **Founded**: 2002
- **Revenue**: €86.1M (FY2025, filed accounts, INPI)
- **SIREN**: [818575730](https://annuaire-entreprises.data.gouv.fr/entreprise/818575730)
- **Website**: [alnylam.com](https://www.alnylam.com/)
- **LinkedIn**: [linkedin.com/company/alnylam-pharmaceuticals](https://www.linkedin.com/company/alnylam-pharmaceuticals)

## Alnylam Pharmaceuticals account plan

Alnylam Pharmaceuticals is an RNAi biopharmaceutical company with six approved medicines, led by AMVUTTRA; about 2,500 employees.

[Read the Alnylam Pharmaceuticals account plan](https://www.tamtam.ai/c/alnylam-pharmaceuticals/account-plan)

## Alnylam Pharmaceuticals in the news

- [Alnylam invests $250m to boost RNAi manufacturing in the US](https://www.europeanpharmaceuticalreview.com/news/269667/alnylam-investment-rnai-manufacturing/) · europeanpharmaceuticalreview.com · Dec 20, 2025
  Alnylam is investing $250 million to expand its Massachusetts facility with an FDA-accepted enzymatic ligation platform to boost RNAi therapeutic manufacturing capacity and reduce costs.
- [Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025](https://ts2.tech/en/alnylam-pharmaceuticals-alny-stock-news-forecasts-and-analyst-outlook-on-dec-20-2025/) · ts2.tech · Dec 20, 2025
  Alnylam Pharmaceuticals is transitioning to a commercial-scale biotech with strong revenue growth from Amvuttra, Nasdaq-100 inclusion, UK reimbursement approval, manufacturing expansion, and ongoing federal scrutiny.
- [Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC](https://www.marketbeat.com/instant-alerts/filing-alnylam-pharmaceuticals-inc-alny-shares-sold-by-us-capital-wealth-advisors-llc-2025-12-20/) · marketbeat.com · Dec 20, 2025
  Alnylam Pharmaceuticals saw notable insider and institutional stock sales amid generally positive analyst ratings, continuing its focus on RNAi therapeutics development.

[See all 20 articles](https://www.tamtam.ai/c/alnylam-pharmaceuticals/news)

## Alnylam Pharmaceuticals at a glance

Alnylam Pharmaceuticals is a B2B company in the Biotechnology Research industry, headquartered in cambridge, massachusetts, United States.

Alnylam Pharmaceuticals was founded in 2002.

Alnylam Pharmaceuticals has 1,001–5,000 employees.

Alnylam Pharmaceuticals's revenue is €86.1M (FY2025, filed accounts, INPI).

Alnylam Pharmaceuticals's SIREN number is 818575730.

## Frequently asked questions about Alnylam Pharmaceuticals

### What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals's revenue is €86.1M (FY2025, filed accounts, INPI).

### How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals has 1,001–5,000 employees.

### Where is Alnylam Pharmaceuticals headquartered?

Alnylam Pharmaceuticals is headquartered in cambridge, massachusetts, United States.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/alnylam-pharmaceuticals
